View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 16, 2021updated 20 Jan 2022 7:26pm

FDA approves Thermo Fisher’s companion diagnostic for Takeda’s NSCLC drug 

Oncomine Dx Target Test can analyse 23 genes linked to NSCLC and is FDA-approved as a CDx for five targeted NSCLC treatments.

Thermo Fisher Scientific has obtained premarket approval from the US Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) for Takeda’s drug for non-small cell lung cancer (NSCLC) patients.

Oncomine Dx Target Test is intended to identify patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive metastatic NSCLC (mNSCLC) who are candidates for Takeda’s Exkivity (mobocertinib).

It can assess 23 genes linked to NSCLC at once.

The test was initially approved by the FDA as a CDx in 2017 and is currently approved for five targeted treatments for NSCLC and one targeted therapy for cholangiocarcinoma in the US.

Furthermore, Oncomine Dx Target Test is cleared by Japan’s Ministry of Health, Labour and Welfare (MHLW) as a CDx for five biomarkers, namely, EGFR; ALK; ROS1; BRAF and RET, which are linked to ten targeted NSCLC treatments.

At present, the test is approved and reimbursed by the government, as well as commercial insurers, in more than 15 countries, including the US, various European nations, Japan, South Korea and the Middle East.

Standard polymerase chain reaction methods can miss half or more of EGFR Exon20 insertion mutations, encouraging diagnostic molecular testing with next-generation sequencing (NGS) technology.

Testing with NGS is vital for early detection and suitable characterisation of tested patients, the company noted.

Thermo Fisher Scientific clinical next-generation sequencing and oncology president Garret Hampton said: “Exkivity offers new hope to previously treated patients with mNSCLC and EGFR Exon20 insertion mutations, who usually do not respond well to other available treatments.

“FDA approval of the Oncomine Dx Target Test as a companion diagnostic for Exkivity will allow clinicians to identify key biomarkers in patients who could benefit from this targeted therapy.

“Working closely with Takeda to scale the clinical adoption of the test as a companion diagnostic for Exkivity is an important next step to enabling precision medicine and potentially improving outcomes of lung cancer patients.”

A small-molecule tyrosine kinase inhibitor (TKI), Exkivity is created to specifically target EGFR Exon20 insertion mutations.

The FDA-approved drug is indicated to treat adult patients with locally advanced or mNSCLC with EGFR Exon20 insertion mutations, as identified by an FDA-cleared test, whose disease has advanced while on or after platinum-based chemotherapy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network